Future Directions: Neoadjuvant Strategies and Personalized Therapy in Advanced RCC

In closing, the panel reflects on where the field of advanced RCC is headed. Neoadjuvant therapy is identified as an area of growing interest, with parallels drawn to other malignancies where preoperative systemic treatment has altered outcomes. Determining which patients benefit most from this approach remains an important research question.

The discussion also addresses the concept of de escalation. As some patients achieve deep and durable responses, investigators are exploring whether treatment intensity can be reduced safely without compromising disease control.

Biomarker integration is viewed as central to the future. Circulating tumor DNA, blood based markers such as KIM-1, and molecular profiling may eventually help guide therapy selection and sequencing more precisely. Understanding resistance mechanisms remains a priority, particularly for patients who do not respond to frontline immune based combinations.

The overarching theme is movement toward more individualized care. Rather than relying solely on fixed algorithms, clinicians aim to match therapy intensity and mechanism to tumor biology and patient specific factors. The session concludes by emphasizing thoughtful, evidence informed decision making in an increasingly complex treatment landscape.